MX2020002788A - Biomarcadores de preeclampsia y sistemas y metodos relacionados. - Google Patents
Biomarcadores de preeclampsia y sistemas y metodos relacionados.Info
- Publication number
- MX2020002788A MX2020002788A MX2020002788A MX2020002788A MX2020002788A MX 2020002788 A MX2020002788 A MX 2020002788A MX 2020002788 A MX2020002788 A MX 2020002788A MX 2020002788 A MX2020002788 A MX 2020002788A MX 2020002788 A MX2020002788 A MX 2020002788A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- related systems
- biomarkers
- preeclampsia
- kits
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4724—Lectins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/50—Fibroblast growth factors [FGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/515—Angiogenesic factors; Angiogenin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Abstract
La presente invención se refiere a métodos, kits, pruebas y sistemas para detectar, predecir, monitorear o descartar la preeclampsia en mujeres embarazadas. También se proporcionan nuevos marcadores de diagnóstico, métodos de análisis de datos, formatos de ensayo y kits que emplean tales marcadores para mejorar una o más características de una prueba para identificar o descartar la preeclampsia con base en biomarcadores de muestras de pacientes.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762558184P | 2017-09-13 | 2017-09-13 | |
PCT/US2018/050893 WO2019055661A1 (en) | 2017-09-13 | 2018-09-13 | PRE-ÉCLAMPSIE BIOMARKERS AND ASSOCIATED SYSTEMS AND METHODS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002788A true MX2020002788A (es) | 2020-09-14 |
Family
ID=65723874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002788A MX2020002788A (es) | 2017-09-13 | 2018-09-13 | Biomarcadores de preeclampsia y sistemas y metodos relacionados. |
Country Status (10)
Country | Link |
---|---|
US (3) | US20200264188A1 (es) |
EP (1) | EP3682250A4 (es) |
JP (1) | JP2020533595A (es) |
KR (1) | KR20200109293A (es) |
CN (1) | CN111094988A (es) |
AU (1) | AU2018331400A1 (es) |
CA (1) | CA3075688A1 (es) |
MX (1) | MX2020002788A (es) |
SG (1) | SG11202002065VA (es) |
WO (1) | WO2019055661A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111094988A (zh) | 2017-09-13 | 2020-05-01 | 普罗根尼蒂公司 | 先兆子痫生物标志物及相关***和方法 |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
GB202012830D0 (en) * | 2020-08-17 | 2020-09-30 | Univ Tartu | Method of prognosing preeclampsia |
CN113724873B (zh) * | 2021-08-31 | 2024-01-12 | 陕西佰美基因股份有限公司 | 一种基于mlp多平台校准的子痫前期风险预测方法 |
Family Cites Families (178)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4777964A (en) | 1986-01-02 | 1988-10-18 | David Briggs | System for obtaining blood samples and submitting for testing of aids |
US5096830A (en) | 1987-11-17 | 1992-03-17 | Adeza Biomedical Corporation | Preterm labor and membrane rupture test |
US5223440A (en) | 1987-11-17 | 1993-06-29 | Adeza Biomedical Corporation | Ex vivo product of conception test to determine abortion |
US5281522A (en) | 1988-09-15 | 1994-01-25 | Adeza Biomedical Corporation | Reagents and kits for determination of fetal fibronectin in a vaginal sample |
US4919889A (en) | 1988-09-15 | 1990-04-24 | Aspen Diagnostics Corporation | Sample collection and transport fluid composition |
WO1993009432A1 (en) | 1991-11-04 | 1993-05-13 | Adeza Biomedical Corporation | Screening method for identifying women at increased risk for imminent delivery |
EP0642667B1 (en) | 1991-11-04 | 2001-01-10 | Adeza Biomedical Corporation | Screening method for identifying women at increased risk for preterm delivery |
US5516702A (en) | 1991-11-06 | 1996-05-14 | Adeza Biomedical Corporation | Screening method for identifying women at increased risk for imminent delivery |
AU6267794A (en) | 1993-02-24 | 1994-09-14 | Dade International Inc. | Immobilization of specific binding assay reagents |
US5898005A (en) | 1993-02-24 | 1999-04-27 | Dade Behring Inc. | Rapid detection of analytes with receptors immobilized on soluble submicron particles |
US5783396A (en) | 1993-03-23 | 1998-07-21 | Voroteliak; Victor | Method of detecting rupture of the amniotic membranes in pregnant mammals |
US5431171A (en) | 1993-06-25 | 1995-07-11 | The Regents Of The University Of California | Monitoring fetal characteristics by radiotelemetric transmission |
ES2135597T3 (es) | 1993-09-03 | 1999-11-01 | Dade Behring Marburg Gmbh | Inmunoensayos fluorescentes de canalizacion del oxigeno. |
US5650394A (en) | 1993-11-04 | 1997-07-22 | Adeza Biomedical | Use of urinastatin-like compounds to prevent premature delivery |
US5597700A (en) | 1994-04-28 | 1997-01-28 | California Research, Llc | Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method |
US5641636A (en) | 1994-05-20 | 1997-06-24 | University Of Pennsylvania | Method of predicting fetal membrane rupture based on matrix metalloproteinase-9 activity |
US6140099A (en) | 1994-05-20 | 2000-10-31 | The Trustees Of The University Of Pennsylvania | Method of delaying fetal membrane rupture by inhibiting matrix metalloproteinase-9 activity |
EP0812353A2 (en) | 1995-01-26 | 1997-12-17 | Merck Frosst Canada Inc. | Prostaglandin receptor dp |
EP0913405B1 (en) | 1995-10-31 | 2006-01-04 | Maruha Corporation | Monoclonal antibody specific for prostaglandin d synthetase |
US6678669B2 (en) | 1996-02-09 | 2004-01-13 | Adeza Biomedical Corporation | Method for selecting medical and biochemical diagnostic tests using neural network-related applications |
US6120460A (en) | 1996-09-04 | 2000-09-19 | Abreu; Marcio Marc | Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions |
US6544193B2 (en) | 1996-09-04 | 2003-04-08 | Marcio Marc Abreu | Noninvasive measurement of chemical substances |
FI963989A (fi) | 1996-10-04 | 1998-04-05 | Wallac Oy | Homogeenisiä määritysmenetelmiä, jotka perustuvat luminesenssienergiasiirtoon |
AU6287198A (en) | 1997-03-07 | 1998-09-29 | Hospital For Sick Children | Methods to diagnose a required regulation of trophoblast invasion |
US6875567B1 (en) | 1997-11-10 | 2005-04-05 | Genentech, Inc. | Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis |
US6610480B1 (en) | 1997-11-10 | 2003-08-26 | Genentech, Inc. | Treatment and diagnosis of cardiac hypertrophy |
US20020031513A1 (en) | 1997-11-24 | 2002-03-14 | Shamir Leibovitz | Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals |
US6267722B1 (en) | 1998-02-03 | 2001-07-31 | Adeza Biomedical Corporation | Point of care diagnostic systems |
US6394952B1 (en) | 1998-02-03 | 2002-05-28 | Adeza Biomedical Corporation | Point of care diagnostic systems |
US6506789B2 (en) | 1998-06-03 | 2003-01-14 | Shionogi & Co., Ltd. | Methods for the treatment of itching comprising administering PGD2 receptor antagonist |
US20010025140A1 (en) | 1998-07-22 | 2001-09-27 | Torok Brian A. | System for identifying premature rupture of membrane during pregnancy |
US6149590A (en) | 1998-07-22 | 2000-11-21 | Smith; Ramada S. | System for identifying premature rupture of membrane during pregnancy |
US6126597A (en) | 1998-07-22 | 2000-10-03 | Smith; Ramada S. | System for identifying premature rupture of membrane during pregnancy |
US7109044B1 (en) | 1998-09-04 | 2006-09-19 | Maruha Corporation | Method of detection and disease state management for renal diseases |
BR9915820A (pt) | 1998-10-29 | 2001-10-30 | Univ Texas | Uso clìnico de tiazolidinadionas sozinhas ou emconjunto com outros agentes para bloquear asações mediadas pela oxitocina, tal comocontrações uterinas em parto prematuro oulactação |
JP2000249709A (ja) | 1999-02-26 | 2000-09-14 | Maruha Corp | 冠血管インターベンション施行後の再狭窄の予測方法 |
US6126616A (en) | 1999-06-21 | 2000-10-03 | Sanyal; Mrinal K. | Collection of biological products from human accessory reproductive organs by absorbent systems |
CA2383135C (en) | 1999-08-23 | 2010-11-30 | Hiroyuki Hirai | Method of identifying properties of substance with respect to human prostaglandin d2 receptors |
FR2809182B1 (fr) | 2000-05-18 | 2003-08-15 | Univ Rene Descartes | Detection de l'il-6 pour la prevision des risques d'accouchement premature |
US20010053876A1 (en) | 2000-06-15 | 2001-12-20 | Torok Brian A. | System for identifying premature rupture of membrane during pregnancy |
US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
US7314727B2 (en) | 2000-07-21 | 2008-01-01 | Maruha Corporation | Methods to facilitate diagnosis of normal pressure hydrocephalus |
US6410583B1 (en) | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
WO2002017770A2 (en) | 2000-08-28 | 2002-03-07 | Morand Patrick G | Use of blood and plasma donor samples and data in the drug discovery process |
US7217725B2 (en) | 2000-09-14 | 2007-05-15 | Allergan, Inc. | Prostaglandin D2 antagonist |
WO2002032958A2 (en) | 2000-10-16 | 2002-04-25 | Bayer Aktiengesellschaft | Polynucleotide and polypeptide sequences of human dendritic cell immunoreceptors |
US7635571B2 (en) | 2000-12-07 | 2009-12-22 | Siemens Healthcare Diagnostics Products Gmbh | Amplified signal in binding assays |
WO2002094830A2 (en) | 2001-05-23 | 2002-11-28 | Merck Frosst Canada & Co. | DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS |
WO2003008978A2 (en) | 2001-07-18 | 2003-01-30 | Merck Frosst Canada & Co. | Eosinophil prostaglandin d2 receptor assays |
US20040197834A1 (en) | 2001-07-20 | 2004-10-07 | Francois Gervais | Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors |
US20050101841A9 (en) | 2001-12-04 | 2005-05-12 | Kimberly-Clark Worldwide, Inc. | Healthcare networks with biosensors |
EP1540341A4 (en) | 2002-07-01 | 2007-01-10 | Univ Rochester Medical Ct | METHOD OF DETERMINING THE PROBABILITY OF RISK OF PREMATURE DELIVERY IN PREGNANT WOMEN |
US7435419B2 (en) | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
OA12890A (en) | 2002-07-19 | 2006-10-13 | Beth Israel Hospital | Methods of diagnosing and treating pre-eclampsia or eclampsia. |
EP2204654B1 (en) | 2002-08-13 | 2012-12-12 | N-Dia, Inc. | Use of devices and methods for detecting amniotic fluid in vaginal secretions |
WO2004021012A2 (en) | 2002-08-29 | 2004-03-11 | Diagnostic Technologies Ltd. | Method of diagnosis of pregnancy-related complications |
WO2004030674A1 (ja) | 2002-09-30 | 2004-04-15 | Shionogi & Co., Ltd. | プロスタグランジンd2、プロスタグランジンd2アゴニストおよびプロスタグランジンd2アンタゴニストの新規用途 |
AU2003284166A1 (en) | 2002-10-23 | 2004-05-13 | University Of Hawaii | Methods for diagnosing and treating pre-term labor |
US20040100376A1 (en) | 2002-11-26 | 2004-05-27 | Kimberly-Clark Worldwide, Inc. | Healthcare monitoring system |
EP1590664A4 (en) | 2003-02-05 | 2007-05-23 | Ciphergen Biosystems Inc | NON-INVASIVE ASSESSMENT OF THE INTRA-NAMINE ENVIRONMENT |
EP1590668A2 (en) | 2003-02-06 | 2005-11-02 | Adeza Biomedical Corporation | Screeninig and treatment methods for prevention of preterm delivery |
US7191068B2 (en) | 2003-03-25 | 2007-03-13 | Proteogenix, Inc. | Proteomic analysis of biological fluids |
US8068990B2 (en) | 2003-03-25 | 2011-11-29 | Hologic, Inc. | Diagnosis of intra-uterine infection by proteomic analysis of cervical-vaginal fluids |
US8003765B2 (en) | 2003-04-09 | 2011-08-23 | Stony Brook Anaesthesiology, University Faculty Practice Corporation | Methods, antibodies and kits for detecting cerebrospinal fluid in a sample |
US20070003992A1 (en) | 2003-04-09 | 2007-01-04 | Pentyala Srinivas N | Methods and kits for detecting cerebrospinal fluid in a sample |
US20040203079A1 (en) | 2003-04-09 | 2004-10-14 | Research Foundation Of The State University Of New York | Methods and kits for detecting cerebrospinal fluid in a sample |
US8060195B2 (en) | 2003-05-02 | 2011-11-15 | The Johns Hopkins University | Devices, systems and methods for bioimpedance measurement of cervical tissue and methods for diagnosis and treatment of human cervix |
CN1791577A (zh) | 2003-05-20 | 2006-06-21 | 麦克弗罗斯特加拿大有限公司 | 氟-甲基磺酰取代的环烷并吲哚和它们作为***素d2拮抗剂的用途 |
WO2005007223A2 (en) | 2003-07-16 | 2005-01-27 | Sasha John | Programmable medical drug delivery systems and methods for delivery of multiple fluids and concentrations |
JP3897117B2 (ja) | 2003-09-24 | 2007-03-22 | マルハ株式会社 | 妊娠中毒症の重症度判定と予知方法、および妊娠中毒症における胎児・胎盤機能の評価方法 |
US20080233597A1 (en) | 2003-09-26 | 2008-09-25 | Yasuhiko Shiina | Method of Detecting or Differentiating Rheumatoid Arthritis and Method of Determining Stage of Disease or Degree of Dysfunction with Regard to Rheumatoid Arthritis |
US20050131287A1 (en) | 2003-12-16 | 2005-06-16 | Kimberly-Clark Worldwide, Inc. | Detection of premature rupture of the amniotic membrane |
US7943294B2 (en) | 2004-07-30 | 2011-05-17 | Hologic, Inc. | Methods for detecting oncofetal fibronectin |
US20080090759A1 (en) | 2004-08-30 | 2008-04-17 | Robert Kokenyesi | Methods and kits for predicting risk for preterm labor |
US20080254479A1 (en) | 2004-08-30 | 2008-10-16 | Cervimark, Llc | Methods and Kits For Predicting Risk For Preterm Labor |
DK1804836T3 (da) | 2004-09-24 | 2011-01-24 | Beth Israel Hospital | Fremgangsmåder til diagnosticering og behandling af graviditetskomplikationer |
GB0422057D0 (en) | 2004-10-05 | 2004-11-03 | Astrazeneca Ab | Novel compounds |
GT200500284A (es) | 2004-10-15 | 2006-03-27 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
JP5009811B2 (ja) | 2004-12-21 | 2012-08-22 | イェール ユニバーシティ | 子癇前症の検出 |
US20060166242A1 (en) | 2005-01-06 | 2006-07-27 | Mount Sinai Hospital | Markers of pre-term labor |
DOP2006000016A (es) | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
GB0505048D0 (en) | 2005-03-11 | 2005-04-20 | Oxagen Ltd | Compounds with PGD antagonist activity |
WO2006102498A2 (en) * | 2005-03-24 | 2006-09-28 | Beth Israel Deaconess Medical Center | Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy |
CA2615081A1 (en) | 2005-07-13 | 2007-01-18 | Eci Biotech Inc. | Substrates, sensors, and methods for assessing conditions in females |
EP1911759A4 (en) | 2005-07-22 | 2010-07-21 | Shionogi & Co | AZAINDOL DERIVATIVE ANTAGONISTIC EFFECT ON PGD2 RECEPTOR |
US7863007B2 (en) | 2005-09-15 | 2011-01-04 | Swiss Asian Property Limited | Marker for prolonged rupture of membranes |
GT200600457A (es) | 2005-10-13 | 2007-04-27 | Aventis Pharma Inc | Sal de fosfato dihidrogeno como antagonistas del receptor de prostaglandina d2 |
WO2007047372A2 (en) | 2005-10-14 | 2007-04-26 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists |
US20070111326A1 (en) | 2005-11-14 | 2007-05-17 | Abbott Laboratories | Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia |
US20080009552A1 (en) | 2006-03-23 | 2008-01-10 | Craig Pennell | Markers of pre-term labor |
AR060403A1 (es) | 2006-04-12 | 2008-06-11 | Sanofi Aventis | Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2 |
SI2037967T1 (sl) | 2006-06-16 | 2017-04-26 | The Trustees Of The University Of Pennsylvania | Antagonisti receptorja za prostaglandin d2 za zdravljenje androgene alopecije |
EP2066628B1 (en) | 2006-07-25 | 2010-10-20 | Sanofi-Aventis | 2-phenyl-indoles as prostaglandin d2 receptor antagonists |
US8133859B2 (en) | 2006-09-27 | 2012-03-13 | The United States Of America As Represented By The Department Of Health And Human Services | SCGB3A2 as a growth factor and anti-apoptotic agent |
DK2083863T3 (da) | 2006-10-03 | 2015-06-22 | Genzyme Corp | Antistoffer mod tgf-beta til anvendelse til behandling af spædbørn med risiko for udvikling af bronkopulmonal dysplasi |
WO2008073491A1 (en) | 2006-12-11 | 2008-06-19 | University Of Florida Research Foundation, Inc. | System and method for analyzing progress of labor and preterm labor |
CA2672373C (en) | 2006-12-19 | 2011-08-30 | Pfizer Products Inc. | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
EP2118652B1 (en) | 2006-12-26 | 2012-05-23 | Brigham Young University | Serum proteomics system and associated methods |
JP2010519328A (ja) | 2007-02-26 | 2010-06-03 | ファイザー・プロダクツ・インク | H−pgdsの阻害剤としてのニコチンアミド誘導体およびプロスタグランジンd2が媒介する疾患の治療のためのそれらの使用 |
US20090058072A1 (en) | 2007-08-30 | 2009-03-05 | Shirlee Ann Weber | Record sheets with integrated themes |
US20100251394A1 (en) | 2007-09-20 | 2010-09-30 | The Johns Hopkins University | Treatment and prevention of ischemic brain injury |
US20110002866A1 (en) | 2007-10-31 | 2011-01-06 | Lubit Beverly W | Methods to prevent a hair-related side effect of treatment with a chemotherapeutic agent |
WO2009059259A2 (en) | 2007-10-31 | 2009-05-07 | Children's Hospital Medical Center | Detection of worsening renal disease in subjects with systemic lupus erythematosus |
US20100298368A1 (en) | 2007-11-06 | 2010-11-25 | Amira Pharmaceuticals, Inc. | Antagonists of pgd2 receptors |
US20110065139A1 (en) | 2007-11-27 | 2011-03-17 | Jacob Mullerad | diagnostic device for identifying rupture of membrane during pregnancy |
US20130177485A1 (en) | 2007-11-27 | 2013-07-11 | Momtec Life Ltd. Of Yazmot Haemek | Diagnostic device for identifying rupture of membrane during pregnancy |
DK2229358T3 (da) | 2007-12-14 | 2011-07-04 | Pulmagen Therapeutics Asthma Ltd | Indoler og deres terapeutiske anvendelse |
EP2235529B1 (en) | 2008-01-07 | 2016-12-14 | Ortho-Clinical Diagnostics, Inc. | Determination of sflt-1:angiogenic factor complex |
EP2245010A1 (en) | 2008-01-18 | 2010-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles active on crth2 receptor |
CA2713229C (en) | 2008-01-25 | 2017-07-11 | Perkinelmer Health Sciences, Inc. | Methods for determining the risk of prenatal complications |
WO2009097584A1 (en) | 2008-01-30 | 2009-08-06 | Proteogenix, Inc. | Maternal serum biomarkers for detection of pre-eclampsia |
WO2009097579A1 (en) | 2008-01-30 | 2009-08-06 | Proteogenix, Inc. | Gestational age dependent proteomic changes of human maternal serum for monitoring maternal and fetal health |
US20110098352A1 (en) | 2008-02-01 | 2011-04-28 | Amira Pharmaceuticals, Inc. | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors |
CN101952244B (zh) | 2008-02-01 | 2014-11-05 | 潘米拉制药公司 | ***素d2受体的n,n-二取代氨基烷基联苯拮抗剂 |
US8242145B2 (en) | 2008-02-14 | 2012-08-14 | Panmira Pharmaceuticals, Llc | Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors |
US8497381B2 (en) | 2008-02-25 | 2013-07-30 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
EP2268611A2 (en) | 2008-04-02 | 2011-01-05 | Amira Pharmaceuticals, Inc. | Aminoalkylphenyl antagonists of prostaglandin d2 receptors |
CA2724542A1 (en) | 2008-05-16 | 2009-11-19 | Corthera, Inc. | Method of administering relaxin to reduce cervical dilation |
US20110112134A1 (en) | 2008-05-16 | 2011-05-12 | Amira Pharmaceuticals, Inc. | Tricyclic Antagonists of Prostaglandin D2 Receptors |
WO2010008864A2 (en) | 2008-06-24 | 2010-01-21 | Amira Pharmaceuticals, Inc. | Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors |
US8071807B2 (en) | 2008-07-03 | 2011-12-06 | Panmira Pharmaceuticals, Llc | Antagonists of prostaglandin D2 receptors |
FR2934681B1 (fr) | 2008-07-29 | 2011-09-30 | Bastien Karkouche | Dispositif pour la capture de particules biologiques et utilisation. |
CA2735525A1 (en) | 2008-08-04 | 2010-02-11 | The Board Of Regents Of The University Of Texas System | Multiplexed diagnostic test for preterm labor |
US8536185B2 (en) | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
GB2463788B (en) | 2008-09-29 | 2010-12-15 | Amira Pharmaceuticals Inc | Heteroaryl antagonists of prostaglandin D2 receptors |
US8378107B2 (en) | 2008-10-01 | 2013-02-19 | Panmira Pharmaceuticals, Llc | Heteroaryl antagonists of prostaglandin D2 receptors |
WO2010042652A2 (en) | 2008-10-08 | 2010-04-15 | Amira Pharmaceuticals, Inc. | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors |
GB2465062B (en) | 2008-11-06 | 2011-04-13 | Amira Pharmaceuticals Inc | Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors |
WO2010057118A2 (en) | 2008-11-17 | 2010-05-20 | Amira Pharmaceuticals, Inc. | Heterocyclic antagonists of prostaglandin d2 receptors |
US9180114B2 (en) | 2008-11-26 | 2015-11-10 | President And Fellows Of Harvard College | Neurodegenerative diseases and methods of modeling |
US20120004233A1 (en) | 2009-01-26 | 2012-01-05 | Amira Pharmaceuticals, Inc | Tricyclic compounds as antagonists of prostaglandin d2 receptors |
US20120046261A1 (en) | 2009-02-27 | 2012-02-23 | University Of Utah Research Foundation | Compositions and methods for diagnosing and preventing spontaneous preterm birth |
GB0905964D0 (en) | 2009-04-06 | 2009-05-20 | King S College London | Marker |
CN102596902A (zh) | 2009-08-05 | 2012-07-18 | 潘米拉制药公司 | Dp2拮抗剂及其用途 |
US20110090048A1 (en) | 2009-09-29 | 2011-04-21 | Li Conan K | Data Transmission Device with User Identification Capability |
US20120270747A1 (en) | 2009-10-29 | 2012-10-25 | The Trustees Of The University Of Pennsylvania | Method of predicting risk of pre-term birth |
RU2556524C2 (ru) | 2009-11-12 | 2015-07-10 | Сервиленц Инк. | Устройства и способы для измерения шейки матки |
WO2011065976A1 (en) | 2009-11-25 | 2011-06-03 | Hologic, Inc. | Detection of intraamniotic infection |
WO2011071893A1 (en) | 2009-12-08 | 2011-06-16 | Cedars-Sinai Medical Center | Diagnostic biomarker to identify women at risk for preterm delivery |
US8874183B2 (en) | 2010-02-18 | 2014-10-28 | The Johns Hopkins University | Preterm labor monitor |
BR112012023039A2 (pt) | 2010-03-16 | 2016-05-17 | Aventis Pharma Inc | pirimidina substituída como um antagonista de receptor prostaglandina d2 |
CN103038228A (zh) | 2010-03-16 | 2013-04-10 | 安万特药物公司 | 作为***素d2受体拮抗剂的取代的嘧啶类化合物 |
TWI562987B (en) | 2010-03-22 | 2016-12-21 | Actelion Pharmaceuticals Ltd | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators |
WO2011119757A2 (en) | 2010-03-23 | 2011-09-29 | The Reproductive Research Technologies, Lp | Noninvasive measurement of uterine emg propagation and power spectrum frequency to predict true preterm labor and delivery |
AU2011240039B2 (en) * | 2010-04-13 | 2017-01-19 | Mycartis Nv | Biomarkers for hypertensive disorders of pregnancy |
EP2569253A4 (en) * | 2010-05-14 | 2013-10-02 | Beth Israel Hospital | EXTRACORPOREAL DEVICES AND METHODS FOR TREATING PREGNANCY COMPLICATIONS |
US20110312927A1 (en) | 2010-06-18 | 2011-12-22 | Satish Kumar Nachaegari | Progesterone Containing Oral Dosage Forms and Related Methods |
US20110312928A1 (en) | 2010-06-18 | 2011-12-22 | Lipocine Inc. | Progesterone Containing Oral Dosage Forms and Related Methods |
US20110318308A1 (en) | 2010-06-25 | 2011-12-29 | Winthrop-University Hospital | Lipocalin-type prostaglandin d2 synthase as a biomarker for lung cancer progression and prognosis |
CA2805452C (en) | 2010-07-05 | 2018-07-31 | Actelion Pharmaceuticals Ltd | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
AP2013006667A0 (en) | 2010-07-12 | 2013-01-31 | Therasyn Sensors Inc | A device and methods for in vivo monitoring of an individual |
US8765487B2 (en) | 2010-09-01 | 2014-07-01 | Clinical Innovations | Detection of amniotic fluid in vaginal secretions of pregnant women due to premature rupture of fetal membranes |
AU2011308615B2 (en) | 2010-10-01 | 2015-02-05 | Hologic, Inc. | Immunoassay test strip for use in a diagnostic system |
US10669569B2 (en) | 2010-10-15 | 2020-06-02 | Navinci Diagnostics Ab | Dynamic range methods |
WO2012076553A2 (en) | 2010-12-06 | 2012-06-14 | Pronota N.V. | Biomarkers and parameters for hypertensive disorders of pregnancy |
GB201101621D0 (en) | 2011-01-31 | 2011-03-16 | Olink Ab | Method and product |
JP2014508290A (ja) | 2011-01-31 | 2014-04-03 | エソテリックス ジェネティック ラボラトリーズ, エルエルシー | 結合分子を用いて微粒子または核酸を富化するための方法 |
US8951996B2 (en) | 2011-07-28 | 2015-02-10 | Lipocine Inc. | 17-hydroxyprogesterone ester-containing oral compositions and related methods |
JP6034394B2 (ja) * | 2011-11-09 | 2016-11-30 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 切迫妊娠高血圧腎症および/またはHELLP症候群の指標としてのsFlt−1またはエンドグリン/PlGF比の動態 |
US20130203068A1 (en) | 2012-02-06 | 2013-08-08 | Perkinelmer Biosignal, Inc. | Dual-acceptor time-resolved-fret |
GB2515983A (en) | 2012-05-08 | 2015-01-07 | Univ Leland Stanford Junior | Methods and compositions for providing a preeclampsia assessment |
KR101996123B1 (ko) | 2012-06-27 | 2019-07-03 | 에프. 호프만-라 로슈 아게 | 특정 시기 내에 임신중독증의 개시를 배제하기 위한 sFlt-1/PlGF 또는 엔도글린/PlGF 비의 적용 수단 및 방법 |
US20140141456A1 (en) | 2012-08-30 | 2014-05-22 | Ansh Labs, LLC | Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia |
ES2690782T3 (es) | 2012-10-24 | 2018-11-22 | Nyu Winthrop Hospital | Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro |
US20150330989A1 (en) * | 2012-11-15 | 2015-11-19 | The Brigham And Women's Hospital, Inc. | Method and system for diagnosing and treating preeclampsia |
CA2903929A1 (en) * | 2013-03-04 | 2014-09-12 | Iq Products B.V. | Prognostic marker to determine the risk for early-onset preeclampsia |
EP3077825B1 (en) * | 2013-12-03 | 2020-11-25 | Cézanne S.A.S. | Method for the selective determination of placental growth factor 2 |
EP3097422B1 (en) | 2014-01-24 | 2018-07-11 | Roche Diagnostics GmbH | Prediction of postpartum hellp syndrome, postpartum eclampsia or postpartum preeclampsia |
US10281475B2 (en) | 2014-03-27 | 2019-05-07 | Wayne State University | Systems and methods to identify and treat subjects at risk for obstetrical complications |
WO2016019176A1 (en) | 2014-07-30 | 2016-02-04 | Matthew Cooper | Methods and compositions for diagnosing, prognosing, and confirming preeclampsia |
US10357469B2 (en) | 2015-02-18 | 2019-07-23 | Aston University | Diagnostic assay and treatment for preeclampsia |
WO2016134324A1 (en) | 2015-02-20 | 2016-08-25 | Neoteryx, Llc | Method and apparatus for acquiring blood for testing |
US20180114600A1 (en) | 2015-03-23 | 2018-04-26 | Adelaide Research & Innovation Pty Ltd | Methods and systems for determining risk of a pregnancy complication occurring |
WO2017042751A1 (en) | 2015-09-11 | 2017-03-16 | Universidad De Los Andes | In vitro method for identifying a pregnancy related disease |
NL2016967B1 (en) | 2016-06-15 | 2017-12-21 | Iq Products B V | Markers and their ratio to determine the risk for early-onset preeclampsia. |
US20190353667A1 (en) | 2017-02-06 | 2019-11-21 | Astute Medical, Inc. | Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure |
US20190079097A1 (en) | 2017-09-13 | 2019-03-14 | Progenity, Inc. | Preeclampsia biomarkers and related systems and methods |
CN111094988A (zh) | 2017-09-13 | 2020-05-01 | 普罗根尼蒂公司 | 先兆子痫生物标志物及相关***和方法 |
-
2018
- 2018-09-13 CN CN201880059588.4A patent/CN111094988A/zh active Pending
- 2018-09-13 KR KR1020207009958A patent/KR20200109293A/ko not_active Application Discontinuation
- 2018-09-13 US US16/646,552 patent/US20200264188A1/en not_active Abandoned
- 2018-09-13 MX MX2020002788A patent/MX2020002788A/es unknown
- 2018-09-13 WO PCT/US2018/050893 patent/WO2019055661A1/en unknown
- 2018-09-13 CA CA3075688A patent/CA3075688A1/en active Pending
- 2018-09-13 EP EP18856306.8A patent/EP3682250A4/en active Pending
- 2018-09-13 JP JP2020515010A patent/JP2020533595A/ja active Pending
- 2018-09-13 SG SG11202002065VA patent/SG11202002065VA/en unknown
- 2018-09-13 AU AU2018331400A patent/AU2018331400A1/en not_active Abandoned
-
2021
- 2021-04-19 US US17/234,574 patent/US11333672B2/en active Active
-
2022
- 2022-03-10 US US17/691,399 patent/US20220268781A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3682250A4 (en) | 2021-03-03 |
US20220268781A1 (en) | 2022-08-25 |
WO2019055661A8 (en) | 2020-03-26 |
WO2019055661A1 (en) | 2019-03-21 |
US11333672B2 (en) | 2022-05-17 |
CN111094988A (zh) | 2020-05-01 |
SG11202002065VA (en) | 2020-04-29 |
EP3682250A1 (en) | 2020-07-22 |
JP2020533595A (ja) | 2020-11-19 |
AU2018331400A1 (en) | 2020-04-02 |
US20200264188A1 (en) | 2020-08-20 |
CA3075688A1 (en) | 2019-03-21 |
KR20200109293A (ko) | 2020-09-22 |
US20210293824A1 (en) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020002788A (es) | Biomarcadores de preeclampsia y sistemas y metodos relacionados. | |
MX2013001042A (es) | Biomarcadores de cancer pancreatico y usos de los mismos. | |
MX2021009726A (es) | Metodos y sistemas para determinar un estado relacionado con el embarazo de un sujeto. | |
MX2020004617A (es) | Prediccion de riesgo de evento cardiovascular y usos del mismo. | |
WO2012177945A3 (en) | Diagnostic methods for eosinophilic esophagitis | |
MX2015016047A (es) | Metodo y sistema para mantener o mejorar el bienestar. | |
EP3182126A3 (en) | Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome | |
EP3029153A3 (en) | Mesothelioma biomarkers and uses thereof | |
IN2014CN01787A (es) | ||
MX355020B (es) | Biomarcadores de cancer de pulmon y usos de los mismos. | |
MX2021006791A (es) | Metodos y composiciones para detectar proteinas mal plegadas. | |
WO2017050939A3 (en) | Method and array for diagnosing pancreatic cancer in an individual | |
MX352035B (es) | Dispositivos, metodos y equipos de prueba para el analisis electronico de analitos. | |
EP3907509A3 (en) | Diagnosis of early stage pancreatic cancer | |
MX2019008911A (es) | Metodos, matrices y usos de estos. | |
MX2019010223A (es) | Sistema de gestion de enfermedad interdisciplinar. | |
BR112018073214A2 (pt) | métodos para a previsão do risco de recorrência da fibrilação atrial, para o diagnóstico de fibrilação atrial em um indivíduo, para o monitoramento de uma terapia e para a classificação da fibrilação e utilizações do biomarcador | |
BR112012031444A2 (pt) | método, arranjo e uso do mesmo | |
WO2016198833A3 (en) | Methods for analysing a urine sample | |
MY195697A (en) | Method of Prognosing and Predicting Breast Cancer Recurrence, Markers Employed Therein and Kit Thereof | |
WO2019089858A3 (en) | Methods of assessing or monitoring a response to a cell therapy | |
MX2020010825A (es) | Sistema y metodo para determinar la salud pulmonar. | |
WO2014161910A3 (en) | Methods and arrays for use in biomarker detection for prostate cancer | |
EP4220171A3 (en) | Markers for endometrial cancer | |
WO2020123880A3 (en) | Genomic rearrangements associated with prostate cancer and methods of using the same |